News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference 28.-30. November 2023 https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-participate-35th-annual-piper-sandler-healthcare?field_nir_news_date_value[min]=

Latest Immunity Bio, Inc. Patents: https://patents.justia.com/patent/11813292

https://last10k.com/sec-filings/IBRX/0001326110-23-000147.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=sentiment&utm_term=ibrx

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity https://ir.immunitybio.com/news-releases/news-release-details/first-data-immunitybios-memory-cytokine-enriched-nk-cells-small?field_nir_news_date_value[min]=

FDA to Study ImmunityBio Cancer Drug https://labusinessjournal.com/healthcare/immunitybio/

LUGPA 2023 Annual Meeting Date: Nov. 2-4 2023 Check out @shovelstocks message on Stocktwits http://stocktwits.com/shovelstocks/message/549863066

https://classic.clinicaltrials.gov/ct2/history/NCT03228667?A=1&B=25&C=Side-by-Side#StudyPageTop

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date https://ir.immunitybio.com/news-releases/news-release-details/fda-accepts-immunitybios-bla-resubmission-complete-and-sets-new?field_nir_news_date_value[min]=

https://www.stocktitan.net/news/IBRX/fda-accepts-immunity-bio-s-bla-resubmission-as-complete-and-sets-new-nqxkdty5z3ur.html

IBRX on X: #ICYMI: @urotoday published an informative piece on the current treatment landscape of BCG-unresponsive non-muscle invasive #bladdercancer. Read on to learn more about N-803 and viral/bacterial-based therapies: https://urotoday.com/library-resources/bladder-cancer/146405-library-resource-the-current-treatment-landscape-of-bcg-unresponsive-non-muscle-invasive-bladder-cancer-n-803-and-viral-bacterial-based-therapies.html…

https://www.syneoshealth.com/careers/jobs/13319712-uro-oncology-business-manager

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-biological-license-application?field_nir_news_date_value[min]=

IL-15 and N-803 for HIV Cure Approaches https://pubmed.ncbi.nlm.nih.gov/37766318/

Besitzverhältnisse: https://ir.immunitybio.com/node/10006/html